Karyopharm Therapeutics Inc  

(Public, NASDAQ:KPTI)   Watch this stock  
Find more results for KPTI
13.86
Aug 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 11.58 - 49.01
Open     -
Vol / Avg. 0.00/720,020.00
Mkt cap 504.96M
P/E     -
Div/yield     -
EPS -3.05
Shares 35.71M
Beta     -
Inst. own 70%
Nov 9, 2015
Q3 2015 Karyopharm Therapeutics Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Aug 12, 2015
Karyopharm Therapeutics Inc at Wedbush PacGrow Healthcare Conference
Aug 10, 2015
Q2 2015 Karyopharm Therapeutics Inc Earnings Release
Aug 10, 2015
Q2 2015 Karyopharm Therapeutics Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -21796.67% -33090.39%
Operating margin -22008.67% -33120.52%
EBITD margin - -32979.48%
Return on average assets -47.23% -40.03%
Return on average equity -50.16% -41.90%
Employees 71 -
CDP Score - -

Address

85 Wells Ave
NEWTON CENTER, MA 02459-3298
United States - Map
+1-617-6580600 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other diseases. The Company is developing small molecule Selective Inhibitor of Nuclear Export (SINE), compounds that inhibits the nuclear export protein XPO1. The Company is seeking the regulatory approval and commercialization of its lead drug candidate, selinexor (KPT-330), as a single orally administered agent in cancer indications with unmet clinical need, initially for hematologic malignancies. It is also advancing the clinical development of selinexor in multiple solid tumor indications. The Company has initiated three registration-directed trials in hematological cancers with selinexor and anticipates initiating a fourth registration-directed trial.

Officers and directors

Sharon Shacham Ph.D. President, Co-Founder, Chief Scientific Officer, Director
Age: 44
Bio & Compensation  - Reuters
Michael G. Kauffman M.D., Ph.D. Co-Founder, Chief Executive Officer and Director
Age: 51
Bio & Compensation  - Reuters
Justin A. Renz Chief Financial Officer, Executive Vice President, Treasurer
Age: 43
Bio & Compensation  - Reuters
Christopher B. Primiano Vice President- Corporate Development, General Counsel, Secretary
Age: 34
Bio & Compensation  - Reuters
Dilara McCauley Ph.D. Vice President - Product Leadership
Bio & Compensation  - Reuters
Brian Austad Ph.D. Senior Director, Head - Pharmaceutical Sciences
Bio & Compensation  - Reuters
Ran Frenkel Chief Development Operations Officer
Age: 46
Bio & Compensation  - Reuters
Barry E. Greene Lead Independent Director
Age: 51
Bio & Compensation  - Reuters
Mikael Dolsten M.D., Ph.D. Director
Age: 56
Bio & Compensation  - Reuters
Mansoor Raza Mirza M.D. Director and Clinical Advisor
Age: 54
Bio & Compensation  - Reuters